

JAMIA HAMDARD
School of Pharmaceutical Education and Research
M. Pharm. I Semester Examination (2023-24)

Subject: Pharmacotherapeutics I
 Paper Code: MPP 102 T

Date: 11-03-2024

Maximum Marks: 75
 Time: Three hours

(Write your Roll No. on the top immediately on receipt of this question paper)

Note: This paper has two Sections; A and B.

Attempt all the two sections.

Section A: Answer all the questions.

Section B: Answer any 4 out of 6 questions

Abbreviations Used:

CO-Course Outcome, PO- Program Outcome, BTL- Bloom Taxonomy Level: BT level 1-Remember; BT level 2-Understand; BT level 3- Apply; BT level 4- Analyze; BT level 5- Evaluate; BT level 6- Create.

SECTION-A

Answer the following in brief (Attempt all questions)

5x3= 15 Marks

Q. No 1	Question	BTL	CO	PO
(a)	Role of apolipoproteins in lipid transport	2	5	1
(b)	Rationale of using sacubitril/valsartan combination in CHF	5	1	1
(c)	Action potential in Automatic vs Non automatic fibers	2	5	1
(d)	Enlist three drug-induced skin disorders with causative agents	1	3	3
(e)	What is 'Reflux esophagitis'?	2	5	1

SECTION B

Long type Questions (Attempt any 4 out of 6)

4x15= 60 Marks

	Question	BTL	CO	PO
Q. No 2	Describe the etiopathogenesis and pharmacotherapy of Acute Coronary Syndrome (ACS).	3	2	1
Q. No 3	Describe the clinical symptoms and treatment of psoriasis	3	4	1
Q. No 4	Write short notes on: a) Insulin preparations b) Drugs used in osteoporosis	1, 3	2	1
Q. No 5	Describe the rationale of using inhaled medications for the management of asthma. What are various aerosol delivery systems used for this purpose?	5	2	1
Q. No 6	What are incretin hormones? Explain the rationale of using incretin-based therapy in the management of Diabetes.	5	2	1
Q. No 7	Describe the evidence-based approach for the management of hypertension in various population groups	5	3	2